In the global CANVAS Program (n = 10,142), CANA, an SGLT2 inhibitor, demonstrated risk reductions in cardiovascular (CV) and renal outcomes in patients with type 2 diabetes and established CV disease or ≥2 CV risk factors. A pre-specified analysis evaluated outcomes in patients from different geographic regions. Overall, 2,430 (24.0%) were from North America, 1,021 (10.1%) were from Central/South America, 3,609 (35.6%) were from Europe, and 3,082 (30.4%) were from the rest of the world. The primary outcome was comprised of CV death, nonfatal myocardial infarction, or nonfatal stroke; other CV and renal outcomes were also analyzed. The primary outcome occurred in 2.80, 2.99, 3.07, and 2.69 patients per 100 patient-years (unadjusted) in North America, Central/South America, Europe, and the rest of the world, respectively. The effects of CANA on the primary outcome were consistent between patients from different geographic regions (interaction P = 0.89) and with the total population (HR [95% CI]: 0.86 [0.75, 0.97]; Figure). Similar effects between subgroups were observed in the individual components of the primary outcome, all-cause mortality, hospitalization for heart failure, and progression of albuminuria. The risk reduction observed with CANA on CV and renal outcomes was consistent across geographic regions.

graphic
View largeDownload slide
Disclosure

C.H. Wysham: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Sanofi. Consultant; Self; AstraZeneca, Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Insulet Corporation, Novo Nordisk Inc., Sanofi. A. Bhattacharyya: None. M. Tsoukas: Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc., Novo Nordisk Inc.. Advisory Panel; Self; Sanofi. Speaker's Bureau; Self; Eli Lilly and Company. E. Martinez-Abundis: Advisory Panel; Self; AstraZeneca. Speaker's Bureau; Spouse/Partner; AstraZeneca. Advisory Panel; Spouse/Partner; AstraZeneca. Speaker's Bureau; Spouse/Partner; AstraZeneca. Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company. Advisory Panel; Spouse/Partner; Eli Lilly and Company. Speaker's Bureau; Spouse/Partner; Eli Lilly and Company. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Research Support; Self; Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc.. Advisory Panel; Spouse/Partner; Janssen Pharmaceuticals, Inc.. Research Support; Spouse/Partner; Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Spouse/Partner; Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Novartis Pharmaceuticals Corporation, Sanofi. Speaker's Bureau; Spouse/Partner; Sanofi. Advisory Panel; Self; Takeda Development Center Americas, Inc.. Speaker's Bureau; Self; Takeda Development Center Americas, Inc.. Advisory Panel; Spouse/Partner; Takeda Development Center Americas, Inc.. Speaker's Bureau; Spouse/Partner; Takeda Development Center Americas, Inc.. Research Support; Self; Merck Sharp & Dohme Corp.. Research Support; Spouse/Partner; Merck Sharp & Dohme Corp., Pfizer Inc.. Advisory Panel; Self; Laboratorios Silanes. Speaker's Bureau; Self; Laboratorios Silanes. Advisory Panel; Spouse/Partner; Laboratorios Silanes. Research Support; Spouse/Partner; Laboratorios Silanes. Speaker's Bureau; Spouse/Partner; Laboratorios Silanes. A. Slee: Other Relationship; Self; Janssen Scientific Affairs, LLC. W. Shaw: Employee; Self; Janssen Research & Development. K.W. Mahaffey: Research Support; Self; Afferent, Amgen, AstraZeneca, Daiichi, Ferring, Google (Verily), Janssen, Medtronic, Merck, Novartis, Sanofi, and St. Jude. Consultant; Self; Ablynx, AstraZeneca, BAROnova, Bio2 Medical, Boehringer Ingelheim, Bristol-Myers Squibb, Cardiometabolic Health Congress, Cubist, Eli Lilly, Elsevier, Epson, GlaxoSmithKline, Janssen, Merck, Mt. Sinai, Radiometer, Springer Publishing, The Medicines Company, Theravance, Vindico, and WebMD. Stock/Shareholder; Self; BioPrint Fitness. D. de Zeeuw: Other Relationship; Self; AbbVie Inc., Astellas Pharma US, Inc., Eli Lilly and Company, Fresenius SE & Co. KGaA, Janssen Scientific Affairs, LLC., Boehringer Ingelheim GmbH, Bayer AG, Mitsubishi Tanabe Pharma Corporation.

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.